August 2020

Join WhatsApp Channel

Mon, 08/31/2020 - 17:13

Job for B.Pharm, M.Sc in Production at Kusum Healthcare Pvt. Ltd

Mon, 08/31/2020 - 17:12

Job for Pharmacist at District Health Society, Dang

District Health Society, Health Branch, Dang District Panchayat, National Health (RCH- NIM) program under Ahwa for filling the vacancies of the following different cadres on a temporary basis on contract basis for the month and then the vacancies on merit basis.

Mon, 08/31/2020 - 17:11

Vacancy for Junior Research Fellow at IISER

Mon, 08/31/2020 - 17:11

Job for Senior Research Fellow / Junior Research Fellow at NII

The National Institute of Immunology (NII) is committed to advanced research addressing the basic mechanisms involved in body's defence to identify modalities for manipulation of the immune system to provide protection against diseases and understand mechanisms that can be used to target disease processes for intervention.

Mon, 08/31/2020 - 17:09

Require Centralized Monitoring Assistant at IQVIA

Read more about A novel approach to separate chiral molecules

Read more about Farxiga demonstrated unprecedented reduction in the risk of kidney failure and cardiovascular or renal death in patients with chronic kidney disease in the Phase III DAPA-CKD trial

Detailed results from the ground-breaking Phase III DAPA-CKD trial showed that AstraZeneca’s Farxiga (dapagliflozin) on top of standard of care reduced the composite measure of worsening of renal function or risk of cardiovascular (CV) or renal death by 39% compared to placebo (p<0.0001) in patients with chronic kidney disease (CKD) Stages 2-4 and elevated urinary albumin excretion. The results were consistent in patients both with and without type-2 diabetes (T2D).

Read more about Bristol Myers Squibb Provides Update on Phase 3 IDHENTIFY Trial in Patients with Relapsed or Refractory Acute Myeloid Leukemia

Bristol Myers Squibb announced that the Phase 3 IDHENTIFY study evaluating IDHIFA® (enasidenib) plus best supportive care (BSC) versus conventional care regimens, which include best supportive care (BSC) only, azacitidine plus BSC, low-dose cytarabine plus BSC or intermediate-dose cytarabine plus BSC, did not meet the primary endpoint of overall survival (OS) in patients with relapsed or refractory acute myeloid leukemia (R/R AML) with an isocitrate dehydrogenase-2 (IDH2) mutation.